Press Releases

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Press Releases

Nov 28, 2012
Porton Down, UK; November 28 2012: GW Pharmaceuticals plc (AIM:GWP) reports results from a Phase IIa exploratory study which has identified GW’s novel cannabinoid, GWP42004, as a potential new oral treatment for type 2 diabetes. In the study, which examined a number of clinically relevant endpoints
Oct 01, 2012
GW Appoints Chris Tovey as Chief Operating Officer London, UK; October 1st 2012: GW Pharmaceuticals plc (AIM: GWP) today announces the appointment, effective today, of Christopher John Tovey to the newly created position of Chief Operating Officer. Chris, aged 47, joins GW having gained a wealth of
Jun 22, 2012
German G-BA establishes positive additional benefit of Sativex® in Multiple Sclerosis Spasticity German G-BA establishes positive additional benefit of Sativex® in Multiple Sclerosis Spasticity German G-BA establishes positive additional benefit of Sativex® in Multiple Sclerosis Spasticity German
May 22, 2012
Porton Down, UK, 22 May 2012: GW Pharmaceuticals plc (AIM: GWP, “GW” or “the Group”), the specialty pharmaceutical company focused on cannabinoid science, announces its interim results for the six months ended 31 March 2012. COMMERCIAL: STRONG PROGRESS Sativex ® in-market sales grow to £5.4m (H1

Ways to keep up to date with GW